Impact of Omicron BA.1 infection on BA.4/5 immunity in transplant recipients.
clinical research/practice
complication: infectious, infection, and infectious agents – viral: SARS-CoV-2/COVID-19
infectious disease
Journal
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
ISSN: 1600-6143
Titre abrégé: Am J Transplant
Pays: United States
ID NLM: 100968638
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
31
08
2022
revised:
10
10
2022
accepted:
20
10
2022
pubmed:
7
2
2023
medline:
25
2
2023
entrez:
6
2
2023
Statut:
ppublish
Résumé
Mutations in the spike protein of SARS-CoV-2 have allowed Omicron subvariants to escape neutralizing antibodies. The degree to which this occurs in transplant recipients is poorly understood. We measured BA.4/5 cross-neutralizing responses in 75 mostly vaccinated transplant recipients who recovered from BA.1 infection. Sera were collected at 1 and 6 months post-BA.1 infection, and a lentivirus pseudovirus neutralization assay was performed using spike constructs corresponding to BA.1 and BA.4/5. Uninfected immunized transplant recipients and health care worker controls were used for comparison. Following BA.1 infection, the proportion of transplant recipients with neutralizing antibody responses was 88.0% (66/75) against BA.1 and 69.3% (52/75) against BA.4/5 (P = .005). The neutralization level against BA.4/5 was approximately 17-fold lower than that against BA.1 (IQR 10.6- to 45.1-fold lower, P < .0001). BA.4/5 responses declined over time and by ≥0.5 log
Identifiants
pubmed: 36744606
pii: S1600-6135(22)27251-7
doi: 10.1016/j.ajt.2022.10.004
pmc: PMC9835003
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
278-283Informations de copyright
Copyright © 2022 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved.
Références
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Cell Rep Med. 2022 Jul 19;3(7):100679
pubmed: 35798000
Nature. 2022 Aug;608(7923):593-602
pubmed: 35714668
Nat Med. 2022 Sep;28(9):1785-1790
pubmed: 35760080
N Engl J Med. 2022 Feb 10;386(6):599-601
pubmed: 35030645
Nat Commun. 2021 Mar 3;12(1):1405
pubmed: 33658502
Transpl Infect Dis. 2021 Aug;23(4):e13637
pubmed: 33993630
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
Science. 2021 Sep 17;373(6561):eabj0299
pubmed: 34529476
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
J Med Virol. 2022 Oct;94(10):4591-4592
pubmed: 35676232
Nat Commun. 2022 Aug 4;13(1):4489
pubmed: 35927279
Transplantation. 2021 Oct 1;105(10):2175-2183
pubmed: 34149003
Nat Med. 2022 Mar;28(3):472-476
pubmed: 35042228
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
J Immunother Cancer. 2021 Jun;9(6):
pubmed: 34117116
Am J Transplant. 2022 Aug;22(8):2089-2093
pubmed: 35266606
JCI Insight. 2020 Oct 2;5(19):
pubmed: 32870820
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
N Engl J Med. 2022 Apr 21;386(16):1579-1580
pubmed: 35294809
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
N Engl J Med. 2022 Jul 7;387(1):86-88
pubmed: 35731894
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Immune Netw. 2022 Aug 03;22(4):e29
pubmed: 36081529
Ann Intern Med. 2021 Sep;174(9):1330-1332
pubmed: 34125572